Dynavax TOLAMBA(TM) Chamber Study Misses Primary Endpoint; Company Updates 2008 Financial Outlook.
Linked as:
Extract
Dynavax TOLAMBA(TM) Chamber Study Misses Primary Endpoint; Company Updates 2008 Financial Outlook.
BERKELEY, Calif. -- Dynavax Technologies Corporation (Nasdaq:DVAX) today reported primary endpoint data from a chamber study of TOLAMBA[TM] that showed a measurable clinical benefit, reducing total nasal symptom score (TNSS) by 41% vs. placebo in 253 patients in the intent-...
See the full content of this document
Sponsored links
